Why Cerus Corporation’s (CERS) Stock Is Down 21.97%
As of Friday, July 31, Cerus Corporation’s CERS share price has dipped by 21.97%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Commentary & Analysis
Why Cerus Corporation’s (CERS) Stock Is Down 26.82%
As of Friday, July 31, Cerus Corporation’s CERS share price has dipped by 26.82%, which has investors questioning if this is right time to buy.Omar Beirat
Why Cerus Corporation’s (CERS) Stock Is Up 5.70%
As of Monday, July 06, Cerus Corporation’s CERS share price has surged by 5.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cerus Corporation’s (CERS) Stock Is Down 5.85%
As of Tuesday, June 30, Cerus Corporation’s CERS share price has dipped by 5.85%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Cerus Corporation’s (CERS) Stock Is Up 7.95%
As of Thursday, June 25, Cerus Corporation’s CERS share price has surged by 7.95%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CERS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $579.1 | $334.8 | 39% |
|
| Shares Out (Mil) | 194.1 | 41.7 | 76% |
|
| Institutional Ownership | 95.2% | 77.3% | 67% |
|
| Float (Mil) | 182.9 | 34.7 | 72% |
|
| Beta | 1.63 | 0.86 | 86% |
|
| Avg Daily Volume (000s) | 2,149 | 266 | 83% |
|
| Price Change (52-week) |
117.3% | 60.7% | 94% |
|
| Growth | CERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.5% | 11.8% | 78% |
|
| Net Income (5yr) | 23.6% | (5.8%) | 78% |
|
| EPS (5yr) | 26.0% | 10.7% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (16.1%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.010) | ($0.030) | $0.000 | |
| Month Ago EPS | ($0.010) | ($0.030) | $0.000 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.025) | ($0.060) | ($0.005) | |
| Year/Year Chg | 25.0% | (63.4%) | (222.0%) | |
| Financials | CERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $217 | $152 | 33% |
|
| Net Income (TTM) (Mil) | ($10) | ($11) | 29% |
|
| EPS (TTM) | ($0.050) | ($0.500) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | $3 | ($2) | 34% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $1 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $42 | $22 | 38% |
|
| Enterprise Value (Q1) (Mil) | $541 | $304 | 35% |
|
| Valuation | CERS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.50 | 2.88 | 88% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | CERS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.0% | 59.1% | 65% |
|
| Net Margin | (4.4%) | (7.7%) | 26% |
|
| ROA | (4.4%) | (13.7%) | 31% |
|
| ROE | (15.5%) | (15.9%) | 25% |
|
| Liabilities to Assets | 69.4% | 44.9% | 65% |
|
| F-Score | 5 | 4 | 51% |
|
Cerus Corporation did not pass any screens on 7/30/2026.
